ATE530667T1 - Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit - Google Patents
Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheitInfo
- Publication number
- ATE530667T1 ATE530667T1 AT06763326T AT06763326T ATE530667T1 AT E530667 T1 ATE530667 T1 AT E530667T1 AT 06763326 T AT06763326 T AT 06763326T AT 06763326 T AT06763326 T AT 06763326T AT E530667 T1 ATE530667 T1 AT E530667T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alzheimer
- kcnn3
- diagnostic
- therapeutic target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68507205P | 2005-05-27 | 2005-05-27 | |
EP05104552 | 2005-05-27 | ||
PCT/EP2006/062667 WO2006125830A2 (en) | 2005-05-27 | 2006-05-29 | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE530667T1 true ATE530667T1 (de) | 2011-11-15 |
Family
ID=35457791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06763326T ATE530667T1 (de) | 2005-05-27 | 2006-05-29 | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit |
Country Status (5)
Country | Link |
---|---|
US (2) | US20090172827A1 (de) |
EP (1) | EP1888783B1 (de) |
JP (1) | JP2008545402A (de) |
AT (1) | ATE530667T1 (de) |
WO (1) | WO2006125830A2 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
FR2929292A1 (fr) * | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
HUP0900431A2 (en) * | 2009-07-10 | 2011-01-28 | Cryo Innovation Kft | Sample imaging system and pocedure for transmitting imager of cells or tissues located in breeder space towards a data processing device |
JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
EP2603524A1 (de) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta-bindende proteine |
US9523673B2 (en) | 2011-10-04 | 2016-12-20 | Psychnostics, Llc | Methods for diagnosing and identifying modulators of membrane potentials in bipolar disorder and attention deficit hyperactivity disorder |
CA3136246A1 (en) | 2019-04-12 | 2020-10-15 | Ultragenyx Pharmaceutical Inc. | Engineered producer cell lines and methods of making and using the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4438391C2 (de) | 1994-10-27 | 1997-07-03 | Evotec Biosystems Gmbh | Vorrichtung zur Bestimmung stoffspezifischer Parameter eines oder weniger Moleküle mittels Korrelations-Spektroskopie |
DE19709348C2 (de) | 1996-05-29 | 1999-07-01 | Schubert Walter Dr Md | Automatisches Multi-Epitop-Ligand-Kartierungsverfahren |
EP0836090A1 (de) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Probenanalyseverfahren durch Bestimmung der spezifischen Helligkeitsverteilung von Teilchen |
DE19649048C1 (de) | 1996-11-27 | 1998-04-09 | Evotec Biosystems Gmbh | Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion |
WO1999003889A1 (en) * | 1997-07-15 | 1999-01-28 | The Regents Of The University Of California | Isolated dna encoding human calcium activated potassium channel |
EP0945718A1 (de) | 1998-03-21 | 1999-09-29 | Evotec BioSystems AG | Ein Verfahren zur Probencharakterisierung durch Bestimmung einer Funktion mindestens einer spezifischen Eigenschaft von Einheiten der Probe |
US6200818B1 (en) | 1997-12-23 | 2001-03-13 | Evotec Biosystems Ag | Method for detecting reactions by means of coincidence analysis |
WO2000052451A1 (en) | 1999-03-03 | 2000-09-08 | Evotec Analytical Systems Gmbh | Homogeneous fluorescence assay |
EP1175602B1 (de) | 1999-04-29 | 2003-03-19 | Evotec OAI AG | Verfahren zur erfassung von fluoreszierenden molekülen oder anderen teilchen mittels erzeugenden funktionen |
US6690463B2 (en) | 2000-02-10 | 2004-02-10 | Evotec Biosystems Ag | Fluorescence intensity and lifetime distribution analysis |
EP1254353B1 (de) | 2000-02-10 | 2004-04-14 | Evotec OAI AG | Fluoreszenzintensitätsanalyse unter verwendung einer vielzahl von verteilungen: konkurrierende bestimmung von diffusionszeiten und molekularer helligkeit |
DE10030798A1 (de) | 2000-06-29 | 2002-01-10 | Evotec Analytical Sys Gmbh | Kompetitives Assay-Verfahren |
US20070269800A9 (en) * | 2002-08-28 | 2007-11-22 | Heinz Von Der Kammer | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases |
US20050010967A1 (en) * | 2003-02-28 | 2005-01-13 | The Regents Of The University Of California | SK3-1B GFP transgenic mouse model for spinocerebellar ataxia and hyperexcitable behavior |
-
2006
- 2006-05-29 US US11/920,734 patent/US20090172827A1/en not_active Abandoned
- 2006-05-29 EP EP06763326A patent/EP1888783B1/de not_active Not-in-force
- 2006-05-29 AT AT06763326T patent/ATE530667T1/de not_active IP Right Cessation
- 2006-05-29 WO PCT/EP2006/062667 patent/WO2006125830A2/en not_active Application Discontinuation
- 2006-05-29 JP JP2008512849A patent/JP2008545402A/ja not_active Withdrawn
-
2010
- 2010-06-02 US US12/792,611 patent/US20110010780A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2006125830A3 (en) | 2007-02-15 |
EP1888783A2 (de) | 2008-02-20 |
US20110010780A1 (en) | 2011-01-13 |
EP1888783B1 (de) | 2011-10-26 |
JP2008545402A (ja) | 2008-12-18 |
US20090172827A1 (en) | 2009-07-02 |
WO2006125830A2 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
ATE461941T1 (de) | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation | |
EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
WO2004065576A3 (en) | Methods and compositions for the treatment of urological disorder using differential expressed polypeptides | |
ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
ATE415632T1 (de) | Verfahren zur diagnose und behandlung von morbus crohn | |
WO2003028543A3 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
WO2004070388A8 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases | |
ATE495269T1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
ATE534751T1 (de) | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit | |
WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
ATE458834T1 (de) | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten | |
ATE465408T1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
WO2005030947A3 (en) | Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases | |
ATE464567T1 (de) | Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen | |
WO2006131562A3 (en) | Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases | |
WO2005101014A3 (en) | Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases | |
WO2005059562A3 (en) | Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases | |
WO2004020665A3 (en) | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases | |
ATE316657T1 (de) | Diagnostische und therapeutische verwendung des caps | |
WO2006008294A3 (en) | Diagnostic and therapeutic use of slim3 for neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |